RUNX1 and acute myeloid leukemia: RUNX1 mutations occur in 10–15% of MDS and have been associated with thrombocytopenia, poor survival with a high risk of progression to AML-MRC, co-occurrence of RAS mutations and loss of chromosome 7/7q [76,77,78].